AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  3  4  5  6  

CDC Updates Interim Recommendations for H1N1 Influenza for HIV-Infected Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"HIV-infected adults and adolescents, especially persons with low CD4 cell counts or AIDS, can experience more severe complications of seasonal influenza. Among patients hospitalized with confirmed 2009 influenza A (H1N1) infections in the United States, the prevalence of certain underlying conditions, including immunosuppressing conditions, has been higher than in the general population suggesting HIV-infected adults and adolescents also might be at higher risk for complications related to infection with 2009 influenza H1N1. ... "This guidance will be updated as more information becomes available, including information o...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 22, 2009 Category: Infectious Diseases Source Type: info

Published Results of Thai HIV Vaccine Study AvailableEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. ...In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 22, 2009 Category: Infectious Diseases Source Type: info

Abacavir/Lamivudine and Tenofovir/Emtricitabine Equal in Efficacy, Not in Side EffectsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“We compared [tenofovir/emtricitabine] TDF-FTC and [abacavir/lamivudine] ABC-3TC in a randomized, open-label, 96-week trial in which either fixed-dose-combination was substituted for current nucleoside treatments in human leukocyte antigen-B*5701-negative adults with human immunodeficiency virus loads <50 copies/mL. … Of 441 patients who were screened, 357 were treated; 98% were men, the mean age was 45 years, 30% were receiving TDF, 20% were receiving ABC, and 24% were receiving a protease inhibitor. Virological failure was uncommon (5.6% for ABC-3TC and 3.9% for TDF-FTC; difference, 1.7%; 95% confidence interval [...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 22, 2009 Category: Infectious Diseases Source Type: info

October 15 is National Latino AIDS Awarenes DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"'National Latino AIDS Awareness Day is a reminder of HIV and AIDS’ heavy impact on the Latino community.  Every nine and a half minutes someone new is infected with HIV, and almost one-fifth of people who are living with HIV and AIDS are Latino.' "'The rate of new HIV infections among Hispanic men is more than double that among white men, with gay and bisexual men particularly affected.  Also the rate of new HIV infections among Hispanic women is nearly four times that of white women.  These people aren’t statistics -- they are our friends, neighbors, and people we love -- and the Centers for Disease ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 14, 2009 Category: Infectious Diseases Source Type: info

NIH Begins H1N1 Vaccine Trial in HIV-Infected Pregnant Women; HIV-Infected Youth and Children's Trial to Begin SoonEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched [October 8, 2009], and a trial to conduct the same test in HIV-infected children and youth will begin [in the coming weeks]. The International Maternal Pediatric Adolescent AIDS Clinical Trials Group is conducting the studies, which are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of the National Institutes of Health. "'These ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 14, 2009 Category: Infectious Diseases Source Type: info

Study Offers New Lead for Antiretroviral Drug DevelopmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study demonstrates that coupling non-catalytic HIV accessory factors with host cell target proteins addressable by high-throughput assays may afford new avenues for the discovery of anti-HIV agents." More information is available: Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 14, 2009 Category: Infectious Diseases Source Type: info

Cardiovascular Risk Factors in Treatment-Naïve People with HIV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Various studies have been conducted to evaluate the role of antiretroviral therapy in the onset of cardiovascular risk among HIV-1-infected patients, while fewer data are available regarding antiretroviral-naïve patients. Our objective was to evaluate the cardiovascular risk among naïve subjects examining traditional risk factors, immunovirologic parameters, assessing the Framingham risk score (FRS), and detecting the presence of subclinical carotid lesions by means of color Doppler ultrasonography. One hundred seventy-two antiretroviral-naïve patients underwent color Doppler ultrasonography.... Thirty-six patients (20...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 14, 2009 Category: Infectious Diseases Source Type: info

VRC Updates Screening Form for Potential VolunteersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), has posted a new confidential screening form to help interested people determine if they are eligible to volunteer for clinical research studies.  Clinical research studies are vital to developing vaccines that ease human suffering; can potentially prevent a pandemic; and, in many cases, save lives. The mission of the VRC is to conduct research that facilitates the development of effective vaccines for hu...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 8, 2009 Category: Infectious Diseases Source Type: info

Study Uses Novel In Vitro Model of HIV-1 Latency to Identify Compounds that Reverse Latency Without Cellular ActivationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe here the development of what we believe to be a novel in vitro model of HIV-1 latency that we used to search for compounds that can reverse latency…. Unlike previously described latency-reversing agents, 5HN activated latent HIV-1 through ROS and NF-kappaB without affecting nuclear factor of activated T cells (NFAT) and PKC, demonstrating that TCR pathways can be dissected and utilized to purge latent virus. Our study expands the number of classes of latency-reversing therapeutics and demonstrates the utility of this in vitro model for finding strategies to eradicate HIV-1 infection.” More information is a...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 8, 2009 Category: Infectious Diseases Source Type: info

Immune-Suppressed HIV Patients are at Risk of Seven Types of CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“The weakened immune systems of people with HIV [put] them at increased risk for at least seven types of cancer, but early diagnosis and treatment of HIV infection could help delay the onset of some of these cancers, a new study suggests.“French researchers examined the incidence of three AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical cancer) and four non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer and anal cancer) in 52,278 HIV-infected people….“Overall, immunodeficiency increased the risk of all the cancers, and CD4 cell count was the most predictive risk fac...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 8, 2009 Category: Infectious Diseases Source Type: info

FDA Approves New Screening Test for Donor Blood Products and OrgansEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The U. S. Food and Drug Administration today announced approval of the Abbott Prism HIV O Plus assay, as a screening tool designed to detect the presence of certain antibodies to HIV. The assay is one of five assays that run on the fully automated Abbott Prism System.... "The Abbott Prism HIV O Plus assay detects antibodies to HIV type 1, groups M and O, and HIV type 2. It is the second donor screening test licensed for the detection of antibodies to HIV type 1, group O. "The Abbott Prism HIV O Plus assay is licensed to screen donated blood and blood specimens from other living donors for these specific types of HIV and...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 1, 2009 Category: Infectious Diseases Source Type: info

Fall 2009 Issue of Mental Health AIDS ReleasedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mental Health AIDS, a quarterly biopsychosocial research update on HIV and mental health, is sponsored by the Center for Mental Health Services (CMHS) of the Substance Abuse and Mental Health Services Administration (SAMHSA) and is disseminated free of charge through the SAMHSA Web site in both PDF and HTML formats. The Fall 2009 issue features "Psychotherapy Select: The Science of Matching Clients to Treatment." In this tool box, a new instrument for identifying individuals who are "ready" for therapy is introduced. The discussion then centers on research findings that can help to promote productive matches between clin...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 1, 2009 Category: Infectious Diseases Source Type: info

Investigational HIV Vaccine Regimen Shows Modest Effect in Preventing HIV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection.  “'These new findings represent an important step forward in HIV vaccine research,' says Anthony S. Fauci, M.D., director of the National Institute...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 24, 2009 Category: Infectious Diseases Source Type: info

Combined Phenotypic and Genotypic Resistance Test for HIV-1 Integrase and Reverse Transcriptase ValidatedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, a genotypic and phenotypic recombinant virus assay was validated for determining resistance against integrase inhibitors. The assays are based on the amplification of a region encompassing not only HIV-1 integrase, but also reverse transcriptase and RNAseH.... Both B and non-B HIV-1 subtypes could be genotyped successfully (93%; 52/56 and 100%; 49/49, respectively) and reproducibly. The phenotypic assay showed a high success rate (96.5%; 139/144) for subtype B (100%; 19/19) and non-B subtypes (92%; 45/49), and was found to be accurate and reproducible as assessed using well-characterized integrase mutants......
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 24, 2009 Category: Infectious Diseases Source Type: info

September 27 is National Gay Men’s HIV/AIDS Awareness DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"On Sept. 27, the second annual National Gay Men’s HIV/AIDS Awareness Day, we pause to mourn the hundreds of thousands of gay and bisexual men who have died with AIDS, and we strengthen our resolve to end this terrible scourge. "In the early years of the HIV/AIDS epidemic in the United States, the virus wreaked most of its initial devastation in this community, cutting short the promising lives of numerous young people and causing heartbreak among the friends and family members of those who became infected and had no good medicines to fight the virus. Since the disease was first recognized in the early 1980s, more than...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 24, 2009 Category: Infectious Diseases Source Type: info

Nominations are Being Accepted for New Scientific/Clinical Members for the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is currently accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is particularly, although not exclusively, seeking candidates with expertise in neurologic complications of HIV infection. The candidates must be recognized experts in HIV medicine with outstanding records of publications and presentations in areas related to antiretroviral therapy. The successful candidates shall serve a 4-year term beginning February 2010, with potential for reappointment for an additional term. The Panel is...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 24, 2009 Category: Infectious Diseases Source Type: info

Nominations are Being Accepted for New Community Members for the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new community representatives to serve a 4-year term beginning February 2010 with potential for reappointment. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents.  The candidate will have knowledge and involvement in issues related to HIV infection in adults, as...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 24, 2009 Category: Infectious Diseases Source Type: info

New Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under WayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"A new, large-scale clinical trial is examining whether antiretroviral medications normally used to treat HIV infection can also prevent HIV infection in women when applied as a vaginal gel or taken as oral tablets once daily. "The study, called Vaginal and Oral Interventions to Control the Epidemic (VOICE) or MTN-003, will involve up to 5,000 HIV-uninfected women at risk for HIV infection in four African countries. The trial will test the safety and efficacy of two different HIV prevention strategies: an investigational microbicide gel containing the antiretroviral drug tenofovir, and oral tablets containing tenofovir or...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 17, 2009 Category: Infectious Diseases Source Type: info

Today is National HIV/AIDS and Aging Awareness DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"HIV/AIDS began its deadly course in the United States mostly as a disease of young men, but today the epidemic touches people of all ages, including adults aged 50 and older. On September 18, the first National HIV/AIDS and Aging Awareness Day, we pause to recognize the importance of preventing HIV infection in this age group and understanding and addressing the unique health effects of the virus on older Americans. "Thanks to the advent of potent, multi-drug therapy against HIV in the mid-1990s, many HIV-infected Americans are living into their 50s and well beyond. Also, while the majority of new HIV infections are in ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 17, 2009 Category: Infectious Diseases Source Type: info

Nominations Currently Being Accepted for New Scientific/Clinical Members for the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is currently accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is particularly, although not exclusively, seeking candidates with expertise in neurologic complications of HIV infection. Panel members critically evaluate new information and prepare guidelines revisions. The candidates must be recognized experts in HIV medicine with outstanding records of publications and presentations in areas related to antiretroviral therapy. The successful candidates shall serve a 4-year term beginning F...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 13, 2009 Category: Infectious Diseases Source Type: info

Nominations Now Being Accepted for New Community Members for the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new community representative(s) to serve a 4-year term beginning February 2010 with potential for reappointment. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents. The candidate will have knowledge and involvement in issues related to HIV infection in adults, as evi...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 13, 2009 Category: Infectious Diseases Source Type: info

Nominations Currently Being Accepted for New Scientific/Clinical Members for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is currently accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is particularly, although not exclusively, seeking candidates with expertise in neurologic complications of HIV infection. Panel members critically evaluate new information and prepare guidelines revisions. The candidates must be recognized experts in HIV medicine with outstanding records of publications and presentations in areas related to antiretroviral therapy. The successful candidates shall serve a 4-year term beginning Fe...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 10, 2009 Category: Infectious Diseases Source Type: info

Nominations Now Being Accepted for New Community Members for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new community representative(s) to serve a 4-year term beginning February 2010 with potential for reappointment. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents. The candidate will have knowledge and involvement in issues related to HIV infection in adults, as evid...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 10, 2009 Category: Infectious Diseases Source Type: info

New Targets for HIV Vaccine IdentifiedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“The discovery of immune system particles that attack the AIDS virus may finally open a way to make a vaccine that could protect people against the deadly and incurable infection … “They used new technology to troll through the blood of 1,800 people infected with the AIDS virus and identified two immune system compounds called antibodies that could neutralize the virus.“And they found a new part of the virus that the antibodies attack, offering a new way to design a vaccine, they reported in the journal Science.... “ ‘The findings themselves are an exciting advance toward the goal of an effective AIDS vaccine...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 10, 2009 Category: Infectious Diseases Source Type: info

Study: Risk Factors for Thrombocytopenia in Era of Potent Antiretroviral Therapy include Hepatitis C Virus Infection, Cirrhosis, and Uncontrolled HIV ReplicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV… We conducted a retrospective-matched case-control study of HIV-infected adult outpatients with and without thrombocytopenia to elucidate the contribution of HIV viremia, hepatitis C infection, and other potential risk factors for thrombocytopenia…Thrombocytopenia in the era of potent antiretroviral therapy is associated with hepatitis C virus infection, cirrhosis, and uncontrolled HIV replicatio...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 10, 2009 Category: Infectious Diseases Source Type: info

CDC: Effective Antiretroviral Therapy May Reduce Transmission Risk of HIVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“Because of [antiretroviral (ART)] medications, many HIV-infected persons are able to reduce levels of virus in the bloodstream (plasma viral load) to undetectable levels. Data suggest that HIV-infected persons with undetectable viral load are less infectious, and may be less likely to transmit HIV via sexual contact.... “Use of ART may be a promising tool for slowing the transmission of HIV within populations if prevention benefits are not offset by increases in risk behavior. Success of such a program will depend critically upon 1) widespread testing and early identification of infected persons, 2) ongoing counselin...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 10, 2009 Category: Infectious Diseases Source Type: info

Increased Rates of HIV-associated Dementia Linked to HIV SubtypeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“The subtype of HIV a person has may determine their odds for progressing to AIDS-linked dementia, Johns Hopkins researchers report. “Cognitive difficulties, even dementia, are a common hallmark of HIV infection. But during their work in Africa, researchers led by Dr. Ned Sacktor noted that people in areas where HIV subtypes A and D were predominant seemed to have especially high rates of dementia…. “Reporting in the September issue of Clinical Infectious Diseases, the team found that seven of 33 patients with HIV subtype A had dementia (24 percent), but of the nine patients infected with subtype D, eight had dem...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 3, 2009 Category: Infectious Diseases Source Type: info

Kidney Function in First-Line Tenofovir-Containing RegimensEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study examined] whether tenofovir disoproxil fumarate (TDF) is associated with renal dysfunction when used as part of an initial antiretroviral regimen and … the effect of ritonavir-boosted protease inhibitor (PI/r) coadministration on renal function in TDF-treated patients … “We compared … antiretroviral-naive patients … who initiated either TDF (n = 201) or any alternative nucleoside reverse transcriptase inhibitor (NRTI) (n = 231) after 1 January 2002 … “Patients taking both TDF and NRTIs experienced an initial decline in eGFR [estimated glomerular filtration rate, a measure of kidney function] duri...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 3, 2009 Category: Infectious Diseases Source Type: info

MMWR Publishes Early Release of the Updated Guidelines for the Prevention and Treatment of Opportunistic Infection in HIV-Exposed and HIV-Infected ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“New guidelines to assist health care workers in preventing and treating the secondary infections that can afflict U.S. children exposed to, or infected with, HIV, were published by the National Institutes of Health and the Centers for Disease Control and Prevention.... “Major changes in the pediatric guidelines include: Emphasis on the importance of effective antiretroviral therapy to improve children’s immune function.… Information on diagnosing and managing immune reconstitution inflammatory syndrome…. Information on the management of antiretroviral therapy in children with opportunistic infections, in...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 27, 2009 Category: Infectious Diseases Source Type: info

FDA and Tibotec Issue Updated Safety Warning for EtravirineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“Tibotec Therapeutics, in cooperation with the U.S. Food and Drug Administration, issued a Dear Healthcare Professional letter to relay important, updated prescribing information for Intelence (etravirine) which reflects an important safety update regarding severe skin and hypersensitivity reactions…. “Specifically, the existing Warning and Precaution regarding Severe Skin Reactions has been strengthened to reflect that there have been postmarketing reports of: fatality due to toxic epidermal necrolysis hypersensitivity reactions, sometimes accompanied by hepatic failure "Additionally, Guidance has been adde...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 27, 2009 Category: Infectious Diseases Source Type: info

HVTN 505 HIV Vaccine Trial Begins Recruiting ParticipantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has opened enrollment in HVTN 505, an exploratory HIV vaccine clinical study examining whether a two-part vaccine regimen can decrease viral load (the amount of HIV in the blood) in study participants who later become infected with HIV. Viral load is an important health indicator in people who are infected with HIV because typically those with less virus remain healthier longer. Further, HIV-infected individuals with reduced levels of virus may be less likely to transmit the virus to other people. "Neither of the two vaccines contains H...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 27, 2009 Category: Infectious Diseases Source Type: info

CDC Continues to Provide Guidance about H1N1 Flu in HIV-Infected AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“CDC, in coordination with state and local health departments and with WHO, is working aggressively to understand the epidemiology of this novel H1N1 flu and determine if it affects HIV-infected people and people with other immunocompromising conditions differently. As additional information about the situation become available, the CDC’s recommendations may change.  Please check the CDC H1N1 Flu website frequently.” More information is available from the CDC: Read What Adults with HIV Infection Should Know About the Novel H1N1 Flu Read Interim Guidance—HIV-Infected Adults and Adolescents: Considerations...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 27, 2009 Category: Infectious Diseases Source Type: info

Please Update Your Contact List: New FAX and International Numbers for AIDSinfoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FAX and international numbers for AIDSinfo have recently changed. Our FAX number is now 1-301-315-2818 and our international number is now 1-301-315-2816. You can also continue to reach us via: Phone: 1-800-HIV-0440 TTY: 1-888-480-3739 Live Help: http://aidsinfo.nih.gov/LiveHelp Email: ContactUs@aidsinfo.nih.gov  Postal mail: P.O. Box 6303, Rockville, MD 20849-6303. Health information specialists are available to answer calls from 12 p.m. to 5 p.m. and Live Help from 12 p.m. to 4 p.m. Eastern Time.
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 20, 2009 Category: Infectious Diseases Source Type: info

We’ve Upgraded Our TTY System!Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
AIDSinfo has implemented a new TTY system to better serve the deaf, hard of hearing, and the speech-impaired community. The new system supports Voice Carry Over (VCO) calls enabling the deaf and hard of hearing to communicate using both voice and text messages. In addition, the new system is equipped with an automated messaging system. Now when the TTY number is called after hours, a message will announce when we’ll be open again. The system also allows callers to leave a text message so that a health information specialist can return the call during the next business day.
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 20, 2009 Category: Infectious Diseases Source Type: info

Synthetic Protein Developed that Blocks HIV Infection in LabEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Researchers report they were able to block HIV infections in the lab with synthetic proteins that prevented the virus from entering healthy cells."In the study, researchers developed synthetic molecules that interfered with the ability of a key HIV protein called gp41 to interact with proteins in host cells."By interrupting the interaction, HIV could not infect the cells, according to the study that appears online Aug. 17 in the Proceedings of the National Academy of Sciences." Read the full story 
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 20, 2009 Category: Infectious Diseases Source Type: info

Study: Immune Systems of Untreated HIV-Infected Individuals May Deteriorate More Quickly than ThoughtEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The immune systems of untreated HIV-infected individuals appear to deteriorate faster than previously thought, according to preliminary results of a small clinical trial. This finding suggests that clinicians may need to monitor people with recent HIV infection as closely as they monitor people with more advanced disease, the study investigators postulate." Read the NIH press release Read the ClinicalTrials.gov page
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 30, 2009 Category: Infectious Diseases Source Type: info

Study: Chronic Alcohol Consumption Affects Short-Term Memory in HIV-Infected IndividualsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The study ... found that more than half of clinic patients with the virus that causes AIDS are also heavy drinkers and they appear to have more problems with short-term episodic memory, while long-term working memory seems unaffected." Read the full story
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 30, 2009 Category: Infectious Diseases Source Type: info

Study: Abacavir/Lamivudine and Tenofovir DF/Emtricitabine Show Comparable Efficacy when Combined with KaletraEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment. This is the first completed, randomized clinical trial to directly compare the efficacy, safety, and tolerability of these agents, each in combination with lopinavir/ritonavir in antiretroviral-naive patients. "Both ABC/3TC and TDF/FTC provided comparable antiviral efficacy, safety, and tolerability when each was combined with lopinavir/ritonavir in treatment-naive patients." Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 30, 2009 Category: Infectious Diseases Source Type: info

At-a-Glance HiatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
AIDSinfo At-a-Glance is going on hiatus for the next few weeks but will be back soon with more weekly HIV/AIDS treatment updates. Thank you for subscribing to AIDSinfo At-a-Glance!
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 30, 2009 Category: Infectious Diseases Source Type: info

Study: Viramune Noninferior to ReyatazEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"A study of 569 patients indicates that ... Viramune suppressed HIV as well as ... Reyataz but had a more favorable effect on cardiovascular risks. The results were presented over the weekend at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa." Read the full story
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 23, 2009 Category: Infectious Diseases Source Type: info

Study: Male Circumcision Does Not Protect Female Partners from HIV InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Circumcision may help protect men from the AIDS virus but it does not protect the wives and female partners of infected men, researchers reported on Thursday. "The disappointed researchers had to stop the trial, which they had hoped would confirm early suggestions that circumcision would protect men and women alike. "But, they said, circumcision is so effective in protecting men that [it] will still likely benefit women indirectly by reducing circulation of the virus in general." Read the full story Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 23, 2009 Category: Infectious Diseases Source Type: info

Study: Antiretrovirals Help Prevent Mother-to-Child HIV Transmission Via Breast MilkEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Antiretroviral drugs appear safe and effective in helping prevent the transmission of HIV from mother to child through breast milk, a new international study has found. "The researchers found that giving daily antiretroviral syrup to breast-feeding infants or putting their HIV-infected mothers on highly active antiretroviral drugs significantly lowered the child's chances of contracting the virus that causes AIDS. ... "In the ... study, HIV-infected mothers and their babies were randomly assigned to one of three groups: infant antiretroviral syrup, maternal medication, or no treatment following birth. After 28 wee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 23, 2009 Category: Infectious Diseases Source Type: info

Study: Nearly One in Four HIV-Infected Women Not Receiving Annual Pap TestEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"HIV-infected women are at increased risk of cervical cytologic abnormalities. HIV treatment guidelines recommend annual Papanicolaou (Pap) tests for HIV-infected women. We assessed screening prevalence and associated factors among HIV-infected women. ... Nearly 1 in 4 women did not receive an annual Pap test. HIV care providers should ensure that HIV-infected women receive annual Pap tests, recognizing that missed Pap tests are more likely among older women and women with low CD4 cell counts. Integrating HIV and gynecologic care and educating clinicians about recommendations may increase screening." Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 20, 2009 Category: Infectious Diseases Source Type: info

Study: Possible Progress on HIV EradicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Latently infected, resting memory CD4+ T cells and macrophages represent a major obstacle to the eradication of HIV-1. For this purpose, "shock and kill" strategies have been proposed (activation of HIV-1 followed by stimuli leading to cell death). Histone deacetylase inhibitors (HDACIs) induce HIV-1 activation from quiescence, yet class/isoform-selective HDACIs are needed to specifically target HIV-1 latency. We tested 32 small molecule HDACIs for their ability to induce HIV-1 activation in the ACH-2 and U1 cell line models. ... The results of the present study may contribute to the future design of class I HDACIs for tr...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 16, 2009 Category: Infectious Diseases Source Type: info

Study: Differences in Disease Progression between HIV-Infected Men and WomenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"HIV-1-infected women tend to have lower viral loads early in HIV-1 infection but progress faster to AIDS for a given viral load than men. Here we show substantial sex differences in the response of plasmacytoid dendritic cells (pDCs) to HIV-1. ... [S]ex differences in TLR-mediated activation of pDCs may account for higher immune activation in women compared to men at a given HIV-1 viral load and provide a mechanism by which the same level of viral replication might result in faster HIV-1 disease progression in women compared to men. Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HI...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 16, 2009 Category: Infectious Diseases Source Type: info

Study: Most HIV-Infected Women Not Receiving Annual Pap TestEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"HIV-infected women are at increased risk of cervical cytologic abnormalities. HIV treatment guidelines recommend annual Papanicolaou (Pap) tests for HIV-infected women. We assessed screening prevalence and associated factors among HIV-infected women. ... Nearly 1 in 4 women did not receive an annual Pap test. HIV care providers should ensure that HIV-infected women receive annual Pap tests, recognizing that missed Pap tests are more likely among older women and women with low CD4 cell counts. Integrating HIV and gynecologic care and educating clinicians about recommendations may increase screening." Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 16, 2009 Category: Infectious Diseases Source Type: info

Study: Long-Acting Injectable Nanoparticles as Possible Antiretroviral Delivery VectorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, this study provides proof-of-concept that 200-nm sized TMC278 nanosuspensions may act as long-acting injectable." Read the study abstract
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 16, 2009 Category: Infectious Diseases Source Type: info

Raltegravir Approved for Treatment-Naive IndividualsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"On July 8, 2009, FDA granted approval to Isentress (raltegravir), for the treatment of HIV-1 infection in treatment-naïve patients. The recommended dose for treatment-naïve adult patients is Isentress 400 mg twice daily, with or without food." Read the press release Read the FDA raltegravir label
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 9, 2009 Category: Infectious Diseases Source Type: info

WHO says TB Vaccine Too Dangerous for HIV-Infected InfantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The World Health Organization is recommending that the Bacille Calmette-Guérin vaccine against tuberculosis be delayed until infants can be tested for HIV. A new WHO study finds BCG, which is routinely given to 75 percent of babies worldwide, is too risky for those born infected with the virus. " Read the full story
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 9, 2009 Category: Infectious Diseases Source Type: info

HIV Inhibits B-Cell Production within Days of Initial InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The antibody response to HIV-1 does not appear in the plasma until approximately 2-5 weeks after transmission, and neutralizing antibodies to autologous HIV-1 generally do not become detectable until 12 weeks or more after transmission. Moreover, levels of HIV-1-specific antibodies decline on antiretroviral treatment. The mechanisms of this delay in the appearance of anti-HIV-1 antibodies and of their subsequent rapid decline are not known. While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effec...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 9, 2009 Category: Infectious Diseases Source Type: info

Pages: 1  2  3  4  5  6